High-Precision Base Editing Clinical Treatment for Sickle Cell Disease — CorrectSequence Therapeutics’ CS-101 Achieves Promising Results in First Patient

SHANGHAI, Aug. 26, 2025 /PRNewswire/ — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle cell…